0.0778 USD
-0.07 (-48.65%)
0.071 USD
-0.01 (-8.74%)
Taking everything into account, VIRX scores 0 out of 10 in our fundamental rating. VIRX was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of VIRX have multiple concerns. VIRX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year VIRX has reported negative net income.
- VIRX had a negative operating cash flow in the past year.
- In the past 5 years VIRX always reported negative net income.
- In the past 5 years VIRX always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -197.14%, VIRX is not doing good in the industry: 90.27% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -197.14% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-82.33%
ROA(5y)-80.57%
ROE(3y)-160.27%
ROE(5y)-134.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- VIRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for VIRX has been increased compared to 1 year ago.
- The debt/assets ratio for VIRX is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -26.24, we must say that VIRX is in the distress zone and has some risk of bankruptcy.
- VIRX has a worse Altman-Z score (-26.24) than 89.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -26.24 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 0.76 indicates that VIRX may have some problems paying its short term obligations.
- With a Current ratio value of 0.76, VIRX is not doing good in the industry: 91.33% of the companies in the same industry are doing better.
- A Quick Ratio of 0.76 indicates that VIRX may have some problems paying its short term obligations.
- VIRX's Quick ratio of 0.76 is on the low side compared to the rest of the industry. VIRX is outperformed by 91.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 11.29% over the past year.
EPS 1Y (TTM)11.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- VIRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.15% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.18%
EPS Next 2Y31.22%
EPS Next 3Y19.14%
EPS Next 5Y14.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VIRX. In the last year negative earnings were reported.
- Also next year VIRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as VIRX's earnings are expected to grow with 19.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.22%
EPS Next 3Y19.14%
5. Dividend
5.1 Amount
- VIRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIRACTA THERAPEUTICS INC / VIRX FAQ
What is the ChartMill fundamental rating of VIRACTA THERAPEUTICS INC (VIRX) stock?
ChartMill assigns a fundamental rating of 0 / 10 to VIRX.
What is the valuation status for VIRX stock?
ChartMill assigns a valuation rating of 0 / 10 to VIRACTA THERAPEUTICS INC (VIRX). This can be considered as Overvalued.
Can you provide the profitability details for VIRACTA THERAPEUTICS INC?
VIRACTA THERAPEUTICS INC (VIRX) has a profitability rating of 0 / 10.
How financially healthy is VIRACTA THERAPEUTICS INC?
The financial health rating of VIRACTA THERAPEUTICS INC (VIRX) is 0 / 10.